Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19...(1400000 186667 Share-bas...),Health

Share-based compensation

liability 618,201 -

Deferred revenue 625,399 350,739

Total current liabilities 8,913,185 6,715,432

Long term portion of deferred revenue 559,419 611,196

Long term portion of debt 33,483,333 7,813,333

Deferred tax liability, non-current 271,706 995,395

Other non-current liabilities 2,627,241 740,321

Total stockholders' equity 123,014,611 123,649,787

Total liabilities and stockholders'

equity $168,869,495 $140,525,464

Non-GAAP Financial Measures and Reconciliations

We use various numerical measures in conference calls, investor meetings

and other forums which are or may be considered "Non-GAAP financial

measures" under Regulation G. We have provided below for your reference

supplemental financial disclosure for these measures, including the most

directly comparable GAAP measure and an associated reconciliation.

Kensey Nash Corporation

Non-GAAP Financial Measures and Reconciliations

Adjusted Income and Earnings Per Share Reconciliation

(Unaudited) Non-GAAP Non-GAAP (Unaudited)

As Reported Adjustments Adjustments As Adjusted

Six Months Six Months

Ended Embolic One-Time Equity Ended

December 31, Protection Acceleration December 31,

2007 2007 2007 2007

Revenues:

Net sales

Biomaterials $21,652,211
'/>"/>